Atara biotherapeutics announces first quarter 2021 financial results and operational progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business highlights and key catalysts over the next 18 months. “atara is off to a strong start in 2021, advancing
ATRA Ratings Summary
ATRA Quant Ranking